Log in to your Inderes Free account to see all free content on this page.
Oncoinvent
Less than 1K followers
ONCIN
Oslo Børs
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.
Read moreMarket cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
20.5.
2026
General meeting '26
27.8.
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Oncoinvent AS: Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies
Oncoinvent AS: BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio